ATRIAN MEDICAL LIMITED

Atrian Medical Limited is a Galway-based medical-technology company dedicated to restoring normal heart rhythm by tackling atrial fibrillation at its source. The firm's core mission is to resolve the condition through a disruptive, science-driven approach that targets the cardiac autonomic nervous system, aiming for a durable solution that reduces the need for repeat procedures.

The company's flagship technology combines epicardial access with pulsed field ablation (PFA) - a gentle, non-thermal energy that selectively disables hyperactive ganglionated plexi while sparing healthy myocardium. Atrian's IP-protected catheters are designed for minimally invasive sub-xiphoid delivery, and the platform has already progressed through first-in-human trials, treating 36 patients across two clinical studies. Backed by over €5 million in funding and a portfolio of worldwide patents originating from the Mayo Clinic, Atrian is positioned to address the high failure rates of current drug and ablation therapies.

By offering a novel, neuron-focused solution, Atrian serves electrophysiologists and cardiac surgeons seeking a more reliable treatment for atrial fibrillation, contributing to a growing market for advanced rhythm-restoration therapies across Ireland and beyond.